Individualized Cutting Edge DNA Test Offers New Hope for PSTS

NextGen Nutritionals has released a new report, which highlights the successful attempt of researchers to create a test that simplifies the process of choosing the right prescription for people suffering from PSTS. Learn more here.

Jacksonville, FL, United States – July 14, 2015 /PressCable/ —

A remarkable new test called GeneSight, uses cutting edge technology to extract DNA from the cheek and then uses an algorithm to analyze eight different genes found in the body to produce an amazing 20,736 results for a possible patient genetic profile.

What makes Genesight different from previously used screening, according to David Dechairo, PhD and Senior Vice President of medical affairs and clinical development for Assurex Health, is the fact that it “looks at genes all together rather than one at a time”. This unique procedure now makes it possible for scientists to then determine appropriate medication choices and doses.

This new method of evaluation can help to determine a total of 787,968 gene medication combination possibilities to apply toward making appropriate choices for treatment. The test uses 38 Federal Drug Administration approved medications which are used to treat a host of depression related issues.

According to the insightful breaking news story, published on Fox news, Melinda Carstensen reports less than hopeful news, reminding readers that “Depression is the most common comorbidity in the United States – exacerbating conditions like diabetes, hypertension, and post-traumatic stress syndrome (PSTS) – but identifying the best medication has historically proved challenging for psychiatrists. Studies show that, on average, when a doctor prescribes an antidepressant, there’s a 50 percent chance it will work, and, if not, there’s only a 25 percent chance the next attempted drug will work.”

With an extremely slim chance for success, it is understandable that patients lose hope. Experts at Nextgen Nutritionals empathize with patients who have not found success with traditional forms of treatment, including psychotherapy and pharmaceuticals, and are pleased to see a possible development in the field. Tom Jones, a representative for the company, was quoted saying, “We share in the exploration of safe and successful remedies that empower people to overcome mental and physical challenges that hinder them.”

To review the full report, readers are invited to visit http://www.nextgennutritionals.com/individualized-dna-test-for-psts. While there, interested parties should feel free to take advantage of the wealth of information available on the company site.

For more information about us, please visit http://www.nextgennutritionals.com

Contact Info:
Name: Yvette Hart
Organization: NextGen Nutritionals
Phone: 1-800-777-4914

Release ID: 86718